Skip to main content
main-content

Genitourinary cancers

Free registration

Medicine Matters is developed for healthcare professionals as

a premier resource for the latest clinical information in medicine.

Expert opinion

Bipolar androgen therapy: Progress and future directions

Bipolar androgen therapy: Progress and future directions

While androgen deprivation has long been a mainstay of treatment for prostate cancer, it has often been overlooked that administration of androgens can also induce anti-tumor responses. Michael Schweizer (University of Washington, Seattle, USA) outlines a new therapy that utilizes both approaches and may potentially have benefit for prostate cancer patients.

Expert opinion

Urinary biomarkers in the management of prostate cancer

Urinary biomarkers in the management of prostate cancer

Non-invasive biomarkers have the potential to guide and improve prostate cancer management in many ways. Maria Frantzi, Agnieszka Latosinska, and Harald Mischak (Mosaiques Diagnostics GmbH, Germany) outline some promising markers and what is needed to implement them in the clinic.

medwireNews@ASCO2018

Need for nephrectomy challenged in some sunitinib-treated metastatic renal cancers

Human kidney cross section

Results of the phase III CARMENA trial show that treatment with sunitinib alone is as good as treatment with nephrectomy followed by sunitinib in patients with intermediate- or poor-risk metastatic renal cell carcinoma.

medwireNews@ASCO2018

IMmotion151 PROs add support for first-line atezolizumab plus bevacizumab in mRCC

Patient-reported outcomes from the IMmotion151 study favor atezolizumab plus bevacizumab as a first-line regimen for the treatment of patients with metastatic clear cell renal cell carcinoma.

medwireNews@ASCO2018

Metastatic CRPC outcomes no worse for Black versus White men

Two studies reported at the ASCO Annual Meeting 2018 show that Black men with metastatic castration-resistant prostate cancer fare as well as White men, if not better, when treated with abiraterone or chemotherapy in the clinical trial setting.

06-07-2018 | Prostate cancer | Editorial | Article

Bipolar androgen therapy: Progress and future directions

While androgen deprivation has long been a mainstay of treatment for prostate cancer, it has often been overlooked that administration of androgens can also induce anti-tumor responses. Michael Schweizer (University of Washington, Seattle, USA) outlines a new therapy that utilizes both approaches and may potentially have benefit for prostate cancer patients.

Author:
Michael Schweizer MD

02-07-2018 | Prostate cancer | Editorial | Article

Urinary biomarkers in the management of prostate cancer

Non-invasive biomarkers have the potential to guide and improve prostate cancer management in many ways. Maria Frantzi, Agnieszka Latosinska, and Harald Mischak (Mosaiques Diagnostics GmbH, Germany) outline some promising markers and what is needed to implement them in the clinic.

Authors:
Maria Frantzi MSc, PhD, Agnieszka Latosinska PhD, Harald Mischak MD, PhD

03-06-2018 | Prostate cancer | ASCO 2018 | Video

Expert commentary: Unpicking the relationship between prostate cancer treatment efficacy, survival and race

ASCO Expert Robert Dreicer reviews two studies looking at differences in survival rates between Black and White men with metastatic castration-resistant prostate cancer (3:16). 

Read the accompanying news story here.

28-04-2017 | Genitourinary cancers | Conference report | Article

Highlights from the 2017 Genitourinary Cancer Symposium (ASCO-GU), Orlando, Florida, USA

Advisory Board member Prof Axel Merseburger discusses the key outcomes from the 2017 ASCO-GU Congress in Orlando, Florida.

Author:
Axel S Merseburger MD

Journal articles and book chapters

29-06-2018 | Castration-resistant prostate cancer | Article

Enzalutamide in Men with Nonmetastatic, Castration-Resistant Prostate Cancer

Hussain M et al. N Engl J Med 2018; 378(26): 2465-2474. doi:10.1056/NEJMoa1800536

14-06-2018 | Renal cell carcinoma | Article

An interdisciplinary consensus on the management of bone metastases from renal cell carcinoma

Grünwald V et al. Nat Rev Urol 2018. doi:10.1038/s41585-018-0034-9.

05-06-2018 | Prostate cancer | Article

Statin use and time to progression in men on active surveillance for prostate cancer

Jayalath VH et al. Prostate Cancer Prostatic Dis 2018. doi:10.1038/s41391-018-0053-x

05-06-2018 | Radiotherapy | Article

Safety of combining radiotherapy with immune-checkpoint inhibition

Hwang WL et al. Nat Rev Clin Oncol 2018. doi: 10.1038/s41571-018-0046-7

04-06-2018 | Renal cell carcinoma | Article

Epigenetics in renal cell cancer: mechanisms and clinical applications

Joosten SC et al. Nat Rev Urol 2018. doi:10.1038/s41585-018-0023-z

27-05-2018 | Prostate cancer | Article

Added Value of Multiparametric Magnetic Resonance Imaging to Clinical Nomograms in Predicting Adverse Pathology in Prostate Cancer

Rayn KN et al. J Urol 2018; pii: S0022-5347(18)43271-5. doi:10.1016/j.juro.2018.05.094

23-05-2018 | Renal cell carcinoma | Article

The efficacy of VEGFR TKI therapy after progression on immune combination therapy in metastatic renal cell carcinoma

Barata PC et al. Br J Cancer 2018. doi:10.1038/s41416-018-0104-z

Images and illustrations

12-04-2018 | Prostate cancer | Images and illustration slides | Collection

Prostate cancer imaging

This downloadable powerpoint slide set presents an overview of the imaging techniques used to assess prostate cancer from initial diagnosis and staging, to evaluation of residual or recurrent disease after treatment. These slides can be used for reference purposes or for inclusion in one’s own slide sets. Source: Vargas HA et al. Prostate Cancer Imaging. In: Bach Am, Zhang J, eds. Atlas of Genitourinary Oncological Imaging. Springer New York.

image credits